1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related

Antibody-drug Conjugate/ADC Related

Antibody-drug Conjugate/ADC Related 相关靶点 (followed by the number of products) :

Antibody-drug Conjugate/ADC Related Antibody-drug Conjugate/ADC Related

Antibody-drug Conjugate/ADC Related

Related Products

PDF 1.82 MB

Overview of Antibody-drug Conjugate/ADC Related:

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy。 The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs。 At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development。

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes。 The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells。 Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs。 Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug。 First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate。 Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins。

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics。



[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

北京pk10怎样玩可以赢钱 北京pk10真好玩 快乐时时彩 在哪里能玩幸运飞艇 北京pk10整合算法 幸运飞艇要怎么玩才能赢 幸运飞艇怎样压注稳赢 幸运飞艇真好玩 怎样玩北京pk10才能赚钱 幸运飞艇怎么样玩才能赢